Background: Previous studies have suggested that platelets are associated with inflammation and steatosis and may play an important role in liver health. Therefore, we evaluated whether antiplatelet agents can improve metabolic disorder-related fatty liver disease (MASLD). Methods: The mice used in the study were fed a high-fat-diet (HFD) and were stratified through liver biopsy at 18 weeks. A total of 22 mice with NAFLD activity scores (NAS) ≥ 4 were randomly divided into three groups (HFD-only, clopidogrel (CLO; 35 mg/kg/day), ticagrelor (TIC; 40 mg/kg/day) group). And then, they were fed a feed mixed with the respective drug for 15 weeks. Blood and tissue samples were collected and used in the study. Results: The TIC group showed a significantly lower degree of NAS and steatosis than the HFD group (p = 0.0047), but no effect on the CLO group was observed. Hepatic lipogenesis markers’ (SREBP1c, FAS, SCD1, and DGAT2) expression and endoplasmic reticulum (ER) stress markers (CHOP, Xbp1, and GRP78) only reduced significantly in the TIC treatment group. Inflammation genes (MCP1 and TNF-α) also decreased significantly in the TIC group, but not in the CLO group. Nile red staining intensity and hepatic lipogenesis markers were reduced significantly in HepG2 cells following TIC treatment. Conclusion: Ticagrelor attenuated NAS and hepatic steatosis in a MASLD mice model by attenuating lipogenesis and inflammation, but not in the CLO group.
Hepatocyte nuclear factor 4 alpha (HNF4α) is a key master transcriptional factor for hepatic fat and bile acid metabolic pathways. We aimed to investigate the role of HNF4α in non-alcoholic fatty liver disease (NAFLD). The role of HNF4α was evaluated in free fatty acid–induced lipotoxicity and chenodeoxycholic acid (CDCA)-induced bile acid toxicity. Furthermore, the role of HNF4α was evaluated in a methionine choline deficiency (MCD)-diet-induced NAFLD model. The overexpression of HNF4α reduced intracellular lipid contents and attenuated palmitic acid (PA)-induced lipotoxicity. However, the protective effects of HNF4α were reversed when CDCA was used in a co-treatment with PA. HNF4α knockdown recovered cell death from bile acid toxicity. The inhibition of HNF4α decreased intrahepatic inflammation and the NAFLD activity score in the MCD model. Hepatic HNF4α inhibition can attenuate bile acid toxicity and be more effective as a therapeutic strategy in NAFLD patients; however, it is necessary to study the optimal timing of HNF4α inhibition.
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and its global incidence continues to increase. MASLD can progress from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, effective preventive and therapeutic options remain limited. In this study, obeticholic acid (OCA) and the probiotic mixture VSL#3 were co-administered to a mouse model of MASLD to modulate gut microbiota and bile acid metabolism. Methods: Male C57BL/6 mice were fed a WD to induce MASLD and treated with OCA, VSL#3, or both. Gut microbiota was analyzed by 16S rRNA sequencing, bile acid (BA) composition was assessed by LC–MS/MS, hepatic and intestinal gene expression was determined by quantitative real-time PCR (qPCR) and immunohistochemistry, and unconjugated OCA pharmacokinetics (PK) were evaluated. Results: VSL#3-containing groups showed differences in selected taxa with reported bile salt hydrolase (BSH) potential and in BA composition, including a numerical shift toward higher levels of deconjugated BAs. Co-administration of OCA and VSL#3 was accompanied by lower hepatic steatosis, numerically favorable serum markers of liver injury, and lower cholesterol and total bilirubin levels. In addition, mice receiving VSL#3 showed numerically higher early plasma concentrations of unconjugated OCA. Lower intestinal ATP-binding cassette subfamily C member 2 (Abcc2) expression was also observed as a separate exploratory finding. Conclusions: The co-administration of VSL#3 with OCA was accompanied by exploratory differences in selected biological parameters and early-phase unconjugated OCA exposure. Lower intestinal Abcc2/Mrp2 expression was observed as a separate exploratory finding, and no functional relationship between intestinal transporter expression and OCA pharmacokinetics was established.
Steatotic liver disease is associated with advanced glycation end-product (AGE) accumulation, but the pathogenic AGE species and mechanisms remain unclear. We investigated whether Nε-(carboxymethyl)lysine (CML) induces hepatic fibrogenic responses and whether CML-associated programs in human liver organoids (HLOs) are reflected in patient biospecimens. AGE–RAGE pathway activity was assessed in three public liver transcriptomic cohorts, and CML and total AGEs were quantified in liver and serum. Models included C57BL/6J mice, HepG2 2D/3D systems, and multicellular HLOs; translational concordance was assessed by serum cytokine and liver proteomic profiling. AGE–RAGE pathway activity was elevated in NASH-related diagnostic and histological categories, and hepatic CML—but not total AGE or serum CML—was increased in steatosis. Oral CML activated AGE–RAGE- and tumor growth factor-β-related programs but caused minimal fibrosis; HepG2 models failed to reproduce CML-driven lipid accumulation. In HLOs, CML induced lipid accumulation and fibrogenic remodeling through a program distinct from oleic acid-driven lipotoxicity. Single-cell RNA sequencing revealed shifts in hepatocyte-, Kupffer-, and stellate-like populations, mitochondrial dysfunction in hepatocyte-like cells, and collagen assembly pathway activation. Functional assays confirmed oxidative stress, NF-κB-dependent cytokine release, stellate cell activation, and collagen deposition; selected responses were attenuated by N-acetylcysteine, clodronate, 2-deoxyglucose, or NF-κB inhibition. Steatosis biospecimens showed partial concordance with CML–HLO-associated inflammatory and fibrogenic programs. Collectively, CML preferentially accumulates in steatotic liver tissue and promotes fibrogenic responses in multicellular HLOs through mitochondrial dysfunction and immune-mediated stellate cell activation. These findings support HLOs as a human-relevant platform for investigating AGE-driven hepatic pathology associated with steatosis.